XPF-001
XPF-001-202
Phase 2 small_molecule completed
Quick answer
XPF-001 for Primary Erythromelalgia is a Phase 2 program (small_molecule) at Xenon Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Xenon Pharmaceuticals
- Indication
- Primary Erythromelalgia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed